leflunomide has been researched along with Recrudescence in 30 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission." | 8.12 | Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study. ( Das, S; Datta, A; Ghosal, A; Goswami, RP; Sarkar, S; Sinha, D, 2022) |
| "To investigate the efficacy and safety of leflunomide (LEF) versus tofacitinib (TOF) in Takayasu arteritis (TAK) patients." | 8.12 | Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. ( Chen, H; Dai, X; Ding, Z; Ji, Z; Jiang, L; Jin, X; Kong, X; Ma, L; Wang, J; Wu, S, 2022) |
| "Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision." | 5.42 | Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015) |
| " This report aims to assess the effectiveness and safety of leflunomide (LEF) in Takayasu arteritis (TA) and giant cell arteritis (GCA)." | 5.41 | Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies. ( Brugarolas, E; Estrada, P; LLop, D; Maymó-Paituvi, P; Narváez, J; Nolla, JM; Palacios-Olid, J; Vidal-Montal, P, 2023) |
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "We report the case of a 60 year female patient suffering from rheumatoid arthritis for the last 25 years, under TNF-blocker and leflunomide, affected by a recurrent pneumothorax with several subpleural nodules, basal bronchiectasis and apical bullous emphysema." | 4.85 | [Referring to an unusual case: pulmonary affection and rheumatoid arthritis]. ( Borges, H; Frey, JG; Schnyder, JM; Tschopp, JM, 2009) |
| "To evaluate the effectiveness of leflunomide as a steroid-sparing agent among Indian patients with giant cell arteritis (GCA) and to assess the changes of "halo sign" within affected arteries, detected ultrasonographically, after remission." | 4.12 | Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study. ( Das, S; Datta, A; Ghosal, A; Goswami, RP; Sarkar, S; Sinha, D, 2022) |
| "To investigate the efficacy and safety of leflunomide (LEF) versus tofacitinib (TOF) in Takayasu arteritis (TAK) patients." | 4.12 | Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. ( Chen, H; Dai, X; Ding, Z; Ji, Z; Jiang, L; Jin, X; Kong, X; Ma, L; Wang, J; Wu, S, 2022) |
| "A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7." | 4.12 | Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. ( Filippa, MG; Panopoulos, S; Sfikakis, PP; Spanos, E; Spanos, G; Tektonidou, MG; Yavropoulou, MP, 2022) |
| " All patients received GCs with a predefined taper regimen starting from a dosage of 0." | 2.94 | Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial. ( Dong, C; Gao, D; Huang, F; Ji, X; Jin, J; Li, K; Li, Y; Liao, S; Luo, G; Wang, H; Wang, X; Wang, Y; Zhang, J; Zhang, Y; Zhao, Y; Zhao, Z; Zhu, J, 2020) |
| "LEF at a dosage of 30 mg/day appears to be effective in the prevention of major relapses in WG, however, this is associated with an increased frequency of adverse events." | 2.73 | Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. ( de Groot, K; Gross, WL; Hellmich, B; Iking-Konert, C; Manger, K; Metzler, C; Miehle, N; Reinhold-Keller, E, 2007) |
| "Leflunomide treatment was initiated at 20 mg/day and increased to 30 mg/day after 12 weeks and, in patients with partial remission, to 40 mg/day after 24 weeks." | 2.71 | Maintenance of remission with leflunomide in Wegener's granulomatosis. ( Fink, C; Gross, WL; Lamprecht, P; Metzler, C; Reinhold-Keller, E, 2004) |
| "In the past, recommendations for the treatment of Wegener's granulomatosis were primarily based on findings reported from open-label clinical trials." | 2.43 | Advances in the therapy of Wegener's granulomatosis. ( Gross, WL; Hellmich, B; Lamprecht, P, 2006) |
| " Clinical manifestation, IgG4-RD responder index (IgG-RD RI), serological indexes, gland ultrasound findings, and adverse drug effect were recorded." | 1.56 | Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. ( Bian, W; Chen, D; Chen, J; Fu, J; Li, Y; Li, Z; Liu, Y; Sun, X; Zhang, W; Zhang, Y; Zhao, X, 2020) |
| "Juvenile idiopathic arthritis is the most common chronic rheumatic disease of childhood resulting in disability in untreated cases." | 1.51 | Leflunomide treatment in juvenile idiopathic arthritis. ( Ayaz, NA; Çakan, M; Çakmak, F; Karadağ, ŞG; Sönmez, HE; Tanatar, A, 2019) |
| "Gender, age, and hypertension are associated with KD recurrence." | 1.43 | Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients. ( Chen, Y; Liu, Z; Wang, J; Xu, F; Zeng, C, 2016) |
| "Episcleritis and scleritis are relatively rare ocular diseases, which are commonly associated with rheumatic diseases including systemic lupus erythematosus (SLE)." | 1.43 | [Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus]. ( Jia, Y; Miao, H; Wang, L; Yang, Y; Zhang, XY; Zhou, YS, 2016) |
| "Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision." | 1.42 | Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015) |
| " No serious adverse events were observed." | 1.39 | Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. ( Lu, W; Xie, L; Xue, W; Yang, S; Yin, A, 2013) |
| "Extensive Wegener's granulomatosis (WG) is treated by glucocorticosteroids (GC) and cyclophosphamide (CYC)." | 1.34 | Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. ( Fritz, J; Henes, JC; Horger, M; Kanz, L; Klein, R; Koch, S; Koetter, I; Risler, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 6 (20.00) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 10 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Das, S | 1 |
| Goswami, RP | 1 |
| Sinha, D | 1 |
| Ghosal, A | 1 |
| Datta, A | 1 |
| Sarkar, S | 1 |
| Wang, J | 2 |
| Dai, X | 1 |
| Ma, L | 2 |
| Wu, S | 1 |
| Jin, X | 1 |
| Ji, Z | 1 |
| Chen, H | 1 |
| Ding, Z | 1 |
| Jiang, L | 1 |
| Kong, X | 1 |
| Yavropoulou, MP | 1 |
| Filippa, MG | 1 |
| Panopoulos, S | 1 |
| Spanos, E | 1 |
| Spanos, G | 1 |
| Tektonidou, MG | 1 |
| Sfikakis, PP | 1 |
| Wang, Y | 2 |
| Zhao, Z | 2 |
| Gao, D | 2 |
| Wang, H | 2 |
| Liao, S | 2 |
| Luo, G | 2 |
| Ji, X | 2 |
| Li, Y | 3 |
| Wang, X | 2 |
| Zhao, Y | 2 |
| Li, K | 2 |
| Zhang, J | 4 |
| Jin, J | 2 |
| Zhang, Y | 3 |
| Zhu, J | 2 |
| Huang, F | 2 |
| Narváez, J | 1 |
| Estrada, P | 1 |
| LLop, D | 1 |
| Vidal-Montal, P | 1 |
| Brugarolas, E | 1 |
| Maymó-Paituvi, P | 1 |
| Palacios-Olid, J | 1 |
| Nolla, JM | 1 |
| Liu, Y | 1 |
| Bian, W | 1 |
| Fu, J | 1 |
| Sun, X | 1 |
| Chen, D | 1 |
| Chen, J | 1 |
| Zhao, X | 1 |
| Zhang, W | 1 |
| Li, Z | 1 |
| Tani, A | 1 |
| Seno, T | 1 |
| Yokoyama, N | 1 |
| Nakagawa, T | 1 |
| Tomiyasu, H | 1 |
| Goto-Koshino, Y | 1 |
| Tsujimoto, H | 1 |
| Ohno, K | 1 |
| Dong, C | 1 |
| Navarro, CE | 1 |
| Enríquez-Ruano, P | 1 |
| Enríquez-Ruano, MN | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Hočevar, A | 1 |
| Ješe, R | 1 |
| Rotar, Ž | 1 |
| Tomšič, M | 1 |
| Lee, JJY | 1 |
| Alsaleem, A | 1 |
| Chiang, GPK | 1 |
| Limenis, E | 1 |
| Sontichai, W | 1 |
| Yeung, RSM | 1 |
| Akikusa, J | 1 |
| Laxer, RM | 1 |
| Ayaz, NA | 1 |
| Karadağ, ŞG | 1 |
| Çakmak, F | 1 |
| Çakan, M | 1 |
| Tanatar, A | 1 |
| Sönmez, HE | 1 |
| Yang, S | 1 |
| Xie, L | 1 |
| Xue, W | 1 |
| Yin, A | 1 |
| Lu, W | 1 |
| Bichler, J | 1 |
| Benseler, SM | 1 |
| Krumrey-Langkammerer, M | 1 |
| Haas, JP | 1 |
| Hügle, B | 1 |
| Chen, Y | 1 |
| Xu, F | 1 |
| Zeng, C | 1 |
| Liu, Z | 1 |
| Wang, L | 1 |
| Yang, Y | 1 |
| Jia, Y | 1 |
| Miao, H | 1 |
| Zhou, YS | 1 |
| Zhang, XY | 1 |
| Kim, SH | 1 |
| Yoo, WH | 1 |
| Borges, H | 1 |
| Schnyder, JM | 1 |
| Frey, JG | 1 |
| Tschopp, JM | 1 |
| Henes, JC | 2 |
| Schedel, J | 1 |
| Kanz, L | 2 |
| Koetter, I | 2 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Carmichael, A | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Adizie, T | 1 |
| Christidis, D | 1 |
| Dharmapaliah, C | 1 |
| Borg, F | 1 |
| Dasgupta, B | 1 |
| Metzler, C | 2 |
| Fink, C | 1 |
| Lamprecht, P | 2 |
| Gross, WL | 3 |
| Reinhold-Keller, E | 2 |
| Hellmich, B | 2 |
| Jayne, D | 1 |
| Fritz, J | 1 |
| Koch, S | 1 |
| Klein, R | 1 |
| Horger, M | 1 |
| Risler, T | 1 |
| Miehle, N | 1 |
| Manger, K | 1 |
| Iking-Konert, C | 1 |
| de Groot, K | 1 |
| Hausen, B | 1 |
| Morris, RE | 1 |
| Guo, Z | 2 |
| Mital, D | 2 |
| Shen, J | 2 |
| Chong, AS | 2 |
| Tian, Y | 2 |
| Foster, P | 2 |
| Sankary, H | 2 |
| McChesney, L | 2 |
| Jensik, SC | 2 |
| Williams, JW | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease[NCT02703194] | Phase 4 | 68 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica[NCT03576794] | Phase 3 | 94 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for leflunomide and Recrudescence
| Article | Year |
|---|---|
Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Topics: Antirheumatic Agents; Cohort Studies; Giant Cell Arteritis; Glucocorticoids; Humans; Leflunomide; Me | 2023 |
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.
Topics: Adult; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathio | 2019 |
Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; M | 2011 |
[Referring to an unusual case: pulmonary affection and rheumatoid arthritis].
Topics: Anti-Bacterial Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Bronchiectasis; Dyspnea; Female; | 2009 |
Advances in the therapy of Wegener's granulomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Etan | 2006 |
Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies.
Topics: Graft Rejection; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lung Transplantation; Ly | 1997 |
3 trials available for leflunomide and Recrudescence
| Article | Year |
|---|---|
Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Topics: Drug Therapy, Combination; Glucocorticoids; Humans; Immunoglobulin G4-Related Disease; Immunosuppres | 2020 |
Maintenance of remission with leflunomide in Wegener's granulomatosis.
Topics: Adult; Aged; Antirheumatic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Granulomatosi | 2004 |
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
Topics: Administration, Oral; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; C-Reactive Protein; Cyclo | 2007 |
20 other studies available for leflunomide and Recrudescence
| Article | Year |
|---|---|
Efficacy of leflunomide as a steroid-sparing agent in treatment of Indian giant cell arteritis patients: A 2-year follow-up study.
Topics: Follow-Up Studies; Giant Cell Arteritis; Humans; Leflunomide; Prednisolone; Recurrence; Steroids | 2022 |
Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study.
Topics: Glucocorticoids; Humans; Immunosuppressive Agents; Leflunomide; Piperidines; Prospective Studies; Py | 2022 |
Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rhe | 2022 |
Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Topics: Chronic Disease; Humans; Immunoglobulin G; Immunoglobulin G4-Related Disease; Leflunomide; Plasma Ce | 2023 |
Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Topics: Adult; Aged; Chromones; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunoglobulin G; Immunog | 2020 |
Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in miniature dachshunds.
Topics: Animals; Colonic Polyps; Cyclosporine; Dog Diseases; Dogs; Female; Immunosuppressive Agents; Japan; | 2020 |
Leflunomide-induced recurrent-transient ischaemic attacks in a patient with rheumatoid arthritis: first case report.
Topics: Aged, 80 and over; Arthritis, Rheumatoid; Humans; Immunosuppressive Agents; Ischemic Attack, Transie | 2020 |
Does leflunomide have a role in giant cell arteritis? An open-label study.
Topics: Aged; Drug Therapy, Combination; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Immunosuppre | 2019 |
Leflunomide treatment in juvenile idiopathic arthritis.
Topics: Adolescent; Arthritis, Juvenile; Biological Products; Child; Child, Preschool; Drug Substitution; Fe | 2019 |
Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biopsy; China; Drug Therapy, Combination; Female; Glo | 2013 |
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Chronic Disease; Cohort Studies; | 2015 |
Clinicopathological features and prognosis of Kimura's disease with renal involvement in Chinese patients.
Topics: Adolescent; Adult; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Inflammatory Agents; China; Fem | 2016 |
[Clinical characteristics of 4 cases of scleritis associated with systemic lupus erythematosus].
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinucle | 2016 |
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; A | 2010 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; Female; Giant Cell Arteritis; H | 2012 |
Leflunomide versus methotrexate in Wegener's granulomatosis.
Topics: Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Isoxazoles; Lef | 2007 |
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
Differential effect of leflunomide on concordant xenogeneic islet graft rejection and recurrence of autoimmune diabetes.
Topics: Animals; Autoimmunity; Diabetes Mellitus, Type 1; Graft Rejection; Immunosuppressive Agents; Islets | 1998 |
Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice.
Topics: Animals; Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Graft Reje | 1998 |